Clinical Access
Clinically Accessed Therapy
This therapy is available exclusively to ROEHN Members and requires asynchronous clinical verification through our licensed telehealth network.
Format
Injectable / Sublingual
Frequency
See instructions
Overview
A next-generation incretin therapy that activates dual metabolic pathways for powerful, sustainable weight reduction and improved metabolic resilience. Tirzepatide simultaneously stimulates GLP-1 and GIP receptors—the two master hormones governing appetite, insulin efficiency, and nutrient utilization. This dual action produces deeper satiety, enhanced glucose control, and a more efficient metabolic rhythm than single-pathway GLP-1 therapies. Infused with methylcobalamin (B12), this formulation supports mitochondrial performance, daily vitality, and neurological clarity—creating a refined, multi-layered approach to metabolic optimization. Aligned with ROEHN’s uncompromising standard of purity, potency, and clinical-grade precision.
Mechanism of Action
GLP-1 Pathway: • Slows gastric emptying • Enhances insulin secretion in glucose-dependent conditions • Reduces hunger signaling • Lowers glucagon levels • Supports caloric reduction without stimulant effect GIP Pathway: • Improves post-meal insulin response • Enhances fat metabolism • Provides an additive appetite-regulating effect Methylcobalamin (B12): • Supports red blood cell formation • Replenishes cellular B12 stores • Enhances mitochondrial energy production • Supports mood and cognitive performance Together, these mechanisms create a highly efficient metabolic environment—one that optimizes energy utilization, stabilizes appetite, and drives sustainable weight loss outcomes.
Key Benefits
Suggested Use
Administered in weekly micro-doses tailored to individual goals. Users typically experience enhanced fullness and reduced appetite within the first 1–2 weeks, with deeper metabolic benefits unfolding over the following month.
